Zalunfiban
Small moleculeexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2019 (NCT03844191)
Timeline
Indications
Mechanism of action
- Integrin alpha-IIb/beta-3INHIBITOR
Integrin alpha-IIb/beta-3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NCC(=O)Nc1cncc(-c2nn3c(=O)cc(N4CCNCC4)nc3s2)c1- Mol. weight
- 386.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3114577 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04825743 | Phase 2 | Apr 24, 2021 | CeleCor Therapeutics, Maastricht University |
| NCT04284995 | Phase 2 | Mar 16, 2020 | CeleCor Therapeutics, Diagram B.V., St. Antonius Hospital, Nieuwegein, Syneos Health |
| NCT03844191 | Phase 1 | Feb 18, 2019 | CeleCor Therapeutics, CirQuest Labs, CRL/Medinet, Precision Medicine |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CeleCor Therapeutics | For profit | 3 | 3 | 2 | 2019 |
| CirQuest Labs | For profit | 1 | 0 | 1 | 2019 |
| CRL/Medinet | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Diagram B.V. | For profit | 1 | 0 | 1 | 2020 |
| Maastricht University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Precision Medicine | For profit | 1 | 0 | 1 | 2019 |
| St. Antonius Hospital, Nieuwegein | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Syneos Health | For profit | 1 | 0 | 1 | 2020 |
8 organizations
Page 1 / 1